With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of other biologics like the IL-12/23 inhibitor Stelara, IL-17 inhibitors such as Cosentyx and Taltz, and IL-23 inhibitors such as Tremfya and Skyrizi. Nonetheless, the early- and late-phase pipeline for moderate to severe psoriasis has several promising agents because drug developers realize that, despite multiple current treatments, novel agents are needed that can differentiate themselves on the attributes of efficacy, safety, convenient delivery, and ability to treat a broad patient population.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 32 European dermatologists fielded in February 2022
Key companies: AbbVie, Novartis, Janssen, Eli Lilly, Amgen
Key drugs: Cosentyx, Humira, Otezla, Skyrizi, Stelara, Taltz, Tremfya